TheraRadar
Data updated: May 26, 2026

NORETHINDRONE ACETATE

Women's Health Approved 2001-05-25

NORETHINDRONE ACETATE is indicated for the treatment of Secondary Amenorrhea; Endometriosis; Abnormal Uterine Bleeding.

6
Indications
--
Phase 3 Trials
25
Years on Market

Details

Status
Prescription
First Approved
2001-05-25
Routes
ORAL
Dosage Forms
TABLET

NORETHINDRONE ACETATE Approval History

2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
10 FDA actions from 2001 to 2018
Nov 2018 ORIGINAL
Update
Nov 2016 ORIGINAL
Update
Jan 2016 ORIGINAL
Update

What NORETHINDRONE ACETATE Treats

3 indications

NORETHINDRONE ACETATE is approved for 3 conditions since its original approval in 2001. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Secondary Amenorrhea
  • Endometriosis
  • Abnormal Uterine Bleeding
Source: FDA Label

NORETHINDRONE ACETATE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 6 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to NORETHINDRONE ACETATE

3 of 9

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

PROVERA
MEDROXYPROGESTERONE ACETATE
2 shared
Pfizer
Shared indications:
Secondary AmenorrheaAbnormal Uterine Bleeding
CLOMIPHENE CITRATE
CLOMIPHENE CITRATE
1 shared
ACCORD HLTHCARE
Shared indications:
Secondary Amenorrhea
CRINONE
PROGESTERONE
1 shared
WATSON LABS INC
Shared indications:
Secondary Amenorrhea
📋

Clinical Trial Registry

4 trials
Trial Sponsor ID Phase Status Title
NCT04527003 results posted STUDY00013752 Ph 3 terminated Cannabidiol and Management of Endometriosis Pain
NCT03970330 results posted Study00011187 Ph 3 terminated Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis
NCT02542410 results posted P00018628 Ph 2 completed Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study
NCT01140217 Simplify NE0906 Ph 3 completed Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NORETHINDRONE ACETATE FDA Label Details

Indications & Usage

FDA Label (PDF)

NORETHINDRONE ACETATE is indicated for the treatment of Secondary Amenorrhea; Endometriosis; Abnormal Uterine Bleeding.

Looking for the branded version?

AYGESTIN

Full clinical data, patents, trials, and competitive landscape for norethindrone acetate.

See AYGESTIN

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.